Global Ophthalmic Drug Delivery Devices Market - 1-3 USERS:2021

Market Report Coverage :
Start Year : 2021 - Forecast Year : 2030 - Start Value : $311.5 Million in 2021 - Forecast Value : $537.8 Million by 2030 - CAGR % : 0.06%
Description :
Market Report Coverage - Ophthalmic Drug Delivery DevicesMarket Segmentation• Product- Pre-filled syringes, multidose eyedroppers, squeeze dispensers, mist sprayers, add-on devices, contact lenses, and others (tubes, ocular inserts, etc.)• Formulation- eye drops, liquid sprays, ointments, gels, and others (emulsions, suspensions, etc.)• Sales channel- Direct sales and indirect sales• End User- Hospitals, clinics, homecare settings, and others (standalone and specialty centers)Regional Segmentation• North America – U.S., and Canada• Europe – Germany, U.K, France, Italy, Spain, Nordic Countries, and Rest-of-Europe• Asia-Pacific – Japan, China, India, South Korea, Australia and New Zealand, Singapore, and Rest-of-Asia-Pacific• Latin America – Brazil, Mexico, Argentina, Colombia, and Rest-of-Latin-America• Middle East and Africa – K.S.A., Israel, South Africa, and Rest-of-Middle East and AfricaMarket Growth Drivers• Rising Prevalence of Ocular Disorders• Development of Novel Drug Dispensers• Integration of Digital Solutions in Ophthalmic Drug Delivery Devices• Regular Funding Cycles for Emerging CompaniesMarket Challenges• High Upfront Cost of Advanced Ophthalmic Drug Delivery Devices• Prolonged Regulatory Approval ProcessMarket Opportunities• Entry of Regional Companies in Global Ophthalmic Drug Delivery Devices Market• Partnerships Between Companies and Ophthalmic Clinics• Inclusion of Nanotechnology in Ophthalmic Drugs FormulationKey Companies ProfiledAero Pump GmbH, AptarGroup, Inc., Bausch Health Companies Inc., Becton, Dickinson and Company, EyePoint Pharmaceuticals, Inc., Gaplast GmbH, Gerresheimer AG, Jotteq Inc., Nemera, Nipro Corporation, Ocular Therapeutix, Inc., Owen Mumford, Silgan Holdings Inc., Terumo Corporation, West Pharmaceutical Services, Inc., Kedalion Therapeutics, Inc., Re-Vana Therapeutics, Mati Therapeutics, Inc., Biocorp, Ocumedic, Inc.How This Report Can Add ValueWho should buy this report?• Technology/non-healthcare companies planning to enter the ophthalmic drug delivery devices market through a platform, mobile application, or smart device• Ophthalmic drug delivery device manufacturers• Companies manufacturing contact lensesKey questions answered in the Global Ophthalmic Drug Delivery Devices Market Report• What has been the impact of COVID-19 on the global ophthalmic drug delivery devices market?• What are the key technological trends influencing the global ophthalmic drug delivery devices market, and what is their potential in short-, mid-, and long-term duration?• What are the key regulations impacting the global ophthalmic drug delivery devices market?• Who are the key players in the global ophthalmic drug delivery devices market? • Which key strategy was most extensively used in the global ophthalmic drug delivery devices market?• What are the key factors influencing the growth of the global ophthalmic drug delivery devices market? What are the major opportunity areas for the companies operating in the market?• Which product sub-category is projected to witness accelerated growth in the global ophthalmic drug delivery devices market during the forecast period 2021-2030?• Which formulation type is projected to hold the largest share in the global ophthalmic drug delivery devices market during the forecast period 2021-2030?• What are the major sales channels in the global ophthalmic drug delivery devices market, and what is their growth potential during the forecast period 2021-2030?• Who are the key end users, and what is their respective share in the global ophthalmic drug delivery devices market?• What are the major key findings for the global ophthalmic drug delivery devices market across various regions?Global Ophthalmic Drug Delivery Devices Market OverviewThe scope of the global ophthalmic drug delivery devices market involves various drug delivery devices used in ophthalmic drug delivery. The considered devices include pre-filled syringes, multidose eyedroppers, drug-eluting contact lenses, technology-enabled add-on devices, mist sprayers, squeeze dispensers, and other devices such as tubes and ocular inserts.The global ophthalmic drug delivery devices market comprises various key medical device companies and emerging companies. The major medical device companies operating in the market include Becton, Dickinson and Company, Nipro Corporation, Teruo Corporation, and West Pharmaceutical Services, Inc.Furthermore, various ophthalmic drug delivery device manufacturers such as Aero Pump GmbH, AptarGroup, Inc., Bausch Health Companies Inc., EyePoint Pharmaceuticals, Inc., Gaplast GmbH, Gerresheimer AG, Jotteq Inc., Nemera, Ocular Therapeutix, Inc., Owen Mumford, and Silgan Holdings Inc. also operate in the market.Additionally, owing to the rising technology integration, various emerging companies such as Kedalion Therapeutics, Inc., Re-Vana Therapeutics, Inc., Biocorp, and Ocumedic, Inc. are also present in the market and are developing advanced ophthalmic drug delivery devices.The factors driving growth include increasing prevalence of ocular disorders, development of novel drug dispensers, integration of digital solutions in ophthalmic drug delivery devices, and regular funding cycles for emerging companies. The restraints for the global ophthalmic drug delivery devices market include high upfront cost of the advanced ophthalmic drug delivery devices and prolonged regulatory approval process. Furthermore, there are various opportunities in the market that hold considerable growth potential. Entry of regional companies in the global ophthalmic drug delivery devices market, partnerships between companies and ophthalmic clinics, and inclusion of nanotechnology in ophthalmic drugs formulation are the key opportunity areas in the global ophthalmic drug delivery devices market.Key technology trends such as the sustained drug delivery, connected devices for medication adherence, small molecules for drug delivery, and liquid sprays are anticipated to influence the global ophthalmic drug delivery devices market.The global ophthalmic drug delivery devices market is in early stages of technology integration. A limited number of patents have been filed in the global market between January 2016-July 2021. According to World Intellectual Property Organisation (WIPO), there were only 148 patents filed pertaining to the global market, with the highest being filed in 2017 (46).During January 2018-June 2021, the global ophthalmic drug delivery devices market witnessed 54 key developments. Regulatory and legal activities were the most actively employed strategies, followed by mergers and acquisitions. The key companies that received regulatory approvals between January 2018-June 2021 included Ocular Therapeutix, Inc., AptarGroup, Inc., EyePoint Pharmaceuticals, Inc., Nemera, Johnson, and Johnson Medical Devices Companies, Bausch and Lomb Incorporated, Ocumedic, Inc, and Terumo Corporation. Similarly, several partnerships took place between January 2018-June 2021. The aim of strategic partnerships includes new product development and business expansion.New product launches are one of the primary strategies adopted by new companies to enter the global ophthalmic drug delivery devices market. Companies have also been working on upgrades for their existing products. Between January 2018-June 2021, several new products were launched in the global ophthalmic drug delivery devices market. Companies such as Gerresheimer AG, Hoffman Neopac AG, Ocular Therapeutix, Inc., and Silgna Holdings, Inc. launched their products in the mentioned period. Furthermore, funding activities are critical for the entry and operation of start-ups in the global ophthalmic drug delivery devices market. Re-Vana Therapeutics, Credence MedSystems, Inc., and Kedalion Therapeutics, Inc. are the prominent companies in the global ophthalmic drug delivery devices market that have received funding for their product development and R&D efforts.Two business models, namely, business-to-customer (B2C) and business-to-business (B2B), are operational in the global ophthalmic drug delivery devices market. The device manufacturers often employ both the business models for ensuring a prominent local and global presence. Moreover, owing to the emergence of add-on devices, the adoption of B2C business model is projected to increase in the market.The global ophthalmic drug delivery devices market report highlights that the market was valued at $295.4 million in 2020 and is expected to reach $537.8 million by the end of 2030. The market is expected to grow at a CAGR of 6.17% during the forecast period from 2021 to 2030.Global Ophthalmic Drug Delivery Devices Market DriversThe factors driving growth include increasing prevalence of ocular disorders, development of novel drug dispensers, integration of digital solutions in ophthalmic drug delivery devices, and regular funding cycles for emerging companies. The rising prevalence of ocular disorders has also increased the global prevalence of blindness. For instance, according to a study published in Lancet, in December 2020, titled ‘Causes of Blindness and Vision Impairment In 2020 and Trends Over 30 Years, and Prevalence of Avoidable Blindness in Relation to VISION 2020: The Right to Sight: An Analysis for the Global Burden of Disease Study,’ cataract was the major cause of blindness. Furthermore, other ocular disorders such as glaucoma, uncorrected refractive error, age-related macular degeneration, and diabetic retinopathy are also the causes of blindness.To overcome the shortcomings of conventional eye droppers, various companies operating in the market have developed either novel dispensing systems or advanced eyedroppers. For instance, companies such as AptarGroup, Inc. and Owen Mumford have developed squeeze dispensers for ophthalmic drug delivery. Furthermore, companies such as Nemera, Aero Pump GmbH, and Berry Healthcare have developed advanced eye droppers with a focus on preservative-free formulation and ease of usage.Furthermore, owing to the rising digitization in the global healthcare system, advancements in drug delivery systems, rising focus on medication adherence, and high cost of drug non-adherence, the ophthalmic drug delivery devices have witnessed digital solutions integration. Companies such as Nemera have developed digital devices for ensuring medication adherence and compliance with the prescribed therapy by the patient. Furthermore, Aptar Group, Inc., in association with Kali Care, has developed connected solutions for ensuring optimum eye care.Furthermore, emerging companies such as Kedalion Therapeutics, Inc., Re-Vana Therapeutics, and Ocumedic, Inc also operate in the global ophthalmic drug delivery devices market. These companies have a strong product pipeline of advanced drug delivery devices with a focus on minimal drug wastage. Moreover, the companies receive regular fundings that ensure constant product development and research and development (R&D) activities.Global Ophthalmic Drug Delivery Devices Market Challenges The restraints for the global ophthalmic drug delivery devices market include high upfront cost of the advanced ophthalmic drug delivery devices and prolonged regulatory approval process.The high upfront cost of the advanced ophthalmic drug delivery devices plays a pivotal role in their limited adoption. For instance, the average price of an ocular insert is approximately $10 per unit, whereas the average price of a pre-filled syringe varies between $0.02-$0.60 per unit. Similarly, the price of a multidose eyedropper varies between $0.03-$0.12. The high price of the advanced ophthalmic drug delivery devices makes their purchase dependent on the reimbursable amount and eligibility criteria. Furthermore, the sales of such devices are considerably low in countries with only private insurance systems.Furthermore, owing to the long duration of regulatory process and additional requirements, the cost of the process increases that further limits the new product launches. Furthermore, the product undergoes the regulatory process in each geography prior to its launch.Global Ophthalmic Drug Delivery Devices Market OpportunitiesEntry of regional companies in the global ophthalmic drug delivery devices market, partnerships between companies and ophthalmic clinics, and inclusion of nanotechnology in ophthalmic drugs formulation are the key opportunity areas in the global ophthalmic drug delivery devices market.The global ophthalmic drug delivery devices market is dominated by global companies such as Nemera, Aptar Group, Inc., Becton, Dickinson and Company, and West Pharmaceutical Services, Inc. However, the market holds significant growth potential for regional companies as well. For instance, Chinese companies are one of the major global suppliers for pre-filled syringes and multidose eyedroppers.Moreover, companies can partner with chain or standalone clinics as business expansion opportunities. Furthermore, partnerships with clinics also facilitate real-world evidence analysis for the companies. The key advantages of such a partnership for a company include the development of a customer base and market presence. Moreover, for patients and ophthalmologists, such a partnership would enable access to advanced drug delivery devices, increased compliance with therapy, and minimal wastage of the drugs.Nanotechnology is one of the key technologies that can be used in manufacturing drug formulations. The key advantages of the technology include sustained drug delivery, target delivery, minimal wastage, and cost-efficacy. Furthermore, such formulations can pass through barriers such as cornea and can be used instead of invasive techniques such as implants.Impact of COVID-19 on Global Ophthalmic Drug Delivery Devices MarketIn the short term, i.e., 2-4 years from 2020, COVID-19 would have a medium impact on the global ophthalmic drug delivery devices market. The demand for add-on devices is anticipated to be high during this timeframe.5-10 years from 2020, the resumption of elective surgeries and normalization of the supply chain would be the key factors for market recovery. Finally, in the long term, i.e., 8-12 years from 2020, the reinstatement of supply chain and entry of advanced ophthalmic drug delivery devices are expected.Market SegmentationGlobal Ophthalmic Drug Delivery Devices Market (by Product)The global ophthalmic drug delivery devices market (by product) has been segmented into pre-filled syringes, multidose eyedroppers, contact lenses, add-on devices, mist sprayers, squeeze dispensers, and others.Global Ophthalmic Drug Delivery Devices Market (by Formulation)The global ophthalmic drug delivery devices market (by formulation) has been segmented into eye drops, liquid sprays, ointments, gels, and others.Global Ophthalmic Drug Delivery Devices Market (by Sales Channel)The global ophthalmic drug delivery devices market has been segmented into direct sales and indirect sales.Global Ophthalmic Drug Delivery Devices Market (by End User)The global ophthalmic drug delivery devices market (by end user) has been segmented into hospitals, clinics, homecare settings, and othersGlobal Ophthalmic Drug Delivery Devices Market (by Region)The different regions covered under the global ophthalmic drug delivery devices market report include North America, Europe, Asia-Pacific, Latin America, and the Middle East, and Africa.North America dominated the global ophthalmic drug delivery devices market in 2018 and is anticipated to uphold its dominance throughout the forecast period. The growth in the market is majorly driven by the increasing research and development activities and adoption of advanced ophthalmic drug delivery devices. Also, the ongoing trend for digital transformation through the development of platforms and mobile applications is putting a significant impact on the market growth.Key Market Players and Competition SynopsisAero Pump GmbH, AptarGroup, Inc., Bausch Health Companies Inc., Becton, Dickinson and Company, EyePoint Pharmaceuticals, Inc., Gaplast GmbH, Gerresheimer AG, Jotteq Inc., Nemera, Nipro Corporation, Ocular Therapeutix, Inc., Owen Mumford, Silgan Holdings Inc., Terumo Corporation, West Pharmaceutical Services, Inc., Kedalion Therapeutics, Inc., Re-Vana Therapeutics, Mati Therapeutics, Inc., Biocorp, and Ocumedic, Inc.The global ophthalmic drug delivery devices market has witnessed several strategic and technological developments in the past few years undertaken by the different market players to attain their respective market shares in this emerging domain. Some of the strategies covered in this segment are regulatory and legal activities, partnerships and alliances, new offerings, mergers and acquisitions, expansion activities, and funding activities.
Countries Covered :
North America U.S. CanadaEurope Germany Italy France Spain U.K. Nordic Countries Rest-of-EuropeAsia-Pacific China India Japan South Korea Australia and New Zealand Rest-of-Asia-PacificLatin America Brazil Mexico Argentina Colombia Rest-of-Latin AmericaMiddle East and Africa K.S.A. Israel South Africa Rest-of-Middle East and Africa
Keywords :
Ophthalmic Drug Delivery Devices Market, Ophthalmic Drug Delivery Devices Industry, Ophthalmic Drug Delivery Devices Report, Ophthalmic Drug Delivery Devices Market Forecasts, Ophthalmic Drug Delivery Devices Market Trends, Ophthalmic Drug Delivery Devices Market Companies, Ophthalmic Drug Delivery Devices Market Analysis, Ophthalmic Drug Delivery Devices Industry Analysis, What is Ophthalmic Drug Delivery Devices, Ophthalmic Drug Delivery Devices Market Definition, Ophthalmic Drug Delivery Devices Market Competitive Landscape, Ophthalmic Drug Delivery Devices Market Drivers, Ophthalmic Drug Delivery Devices Market Segments, Ophthalmic Drug Delivery Devices Market Outlook, Ophthalmic Drug Delivery Devices Market Opportunity, Ophthalmic Drug Delivery Devices Market Growth, Ophthalmic Drug Delivery Devices Market Share, Ophthalmic Drug Delivery Devices Market Size, Ophthalmic Drug Delivery Devices Market by Product, Ophthalmic Drug Delivery Devices Market by Formulation, Ophthalmic Drug Delivery Devices Market by Sales Channel, Ophthalmic Drug Delivery Devices Market by End User, Ophthalmic Drug Delivery Devices Market by Region, Pre-Filled Syringes Ophthalmic Drug Delivery Devices Market, Multidose Eyedroppers Ophthalmic Drug Delivery Devices Market, Squeeze Dispenser Ophthalmic Drug Delivery Devices Market, Mist Sprayers Ophthalmic Drug Delivery Devices Market, Add-On Devices Ophthalmic Drug Delivery Devices Market, Contact Lenses Ophthalmic Drug Delivery Devices Market, Eye Drops Ophthalmic Drug Delivery Devices Market, Liquid Sprays Ophthalmic Drug Delivery Devices Market, Ointments Ophthalmic Drug Delivery Devices Market, Gels Ophthalmic Drug Delivery Devices Market, Tubes Ophthalmic Drug Delivery Devices Market, Ocular Inserts Ophthalmic Drug Delivery Devices Market, Emulsions Ophthalmic Drug Delivery Devices Market, Suspensions Ophthalmic Drug Delivery Devices Market, Direct Sales Ophthalmic Drug Delivery Devices Market, Indirect Sales Ophthalmic Drug Delivery Devices Market, Hospitals Ophthalmic Drug Delivery Devices Market, Clinics Ophthalmic Drug Delivery Devices Market, Homecare Settings Ophthalmic Drug Delivery Devices Market, Standalone Ophthalmic Drug Delivery Devices Market, Specialty Centers Ophthalmic Drug Delivery Devices Market, North America Ophthalmic Drug Delivery Devices Market, Europe Ophthalmic Drug Delivery Devices Market, Asia-Pacific Ophthalmic Drug Delivery Devices Market, Latin America Ophthalmic Drug Delivery Devices Market, Middle East and Africa Ophthalmic Drug Delivery Devices Market
Press Release :
The global ophthalmic drug delivery devices market is projected to reach $537.8 million by 2030, reveals the premium market intelligence study by BIS Research. The study also highlights that the market is set to witness a CAGR of 6.17% during the period 2021-2030.The comprehensive study of the global ophthalmic drug delivery devices market by BIS Research extensively covers the following:• Market numbers on various ophthalmic drug delivery devices, formulations, sales channels, and end users• More than 100 products present in the market• Market share analysis for ophthalmic drug delivery devices• Detailed global and regional market share analysis, including the scrutiny of 21 countries • Study of data of more than 30 companiesOcular or ophthalmic conditions have become one of the primary concerns in the global healthcare ecosystem. For instance, according to the World Health Organization (WHO)’s World Report on Vision report, published in October 2019, approximately 2.2 billion people suffer from some form of vision condition around the world. Furthermore, out of the 2.2 billion people impacted, 1 billion people suffer from a preventable or undiagnosed form of impairment. Moreover, the prevalence of ocular disorders is rising unequally, with low- and mid-income countries being adversely impacted. The integration of technology in ophthalmic drug delivery is projected to increase medication adherence and ensure sustained drug delivery. Furthermore, key players in the market comprise key medical device companies and emerging players. The emerging players are focusing on the development of advanced ophthalmic drug delivery devices.However, owing to the COVID-19 pandemic, the market’s growth declined in 2020. The shutdown of elective procedures and disruption in supply chains were the major factors for the market decline. However, the market is expected to normalize from 2021 as the surgeries resume.Also, the global ophthalmic drug delivery devices market is expected to be influenced by various trends such as sustained drug delivery, connected devices for medication adherence, small molecules for drug delivery, and liquid sprays.Key Companies Operating in the MarketLeading companies, market participants, and vendors operating in the market include Aero Pump GmbH, AptarGroup, Inc., Bausch Health Companies Inc., Becton, Dickinson and Company, EyePoint Pharmaceuticals, Inc., Gaplast GmbH, Gerresheimer AG, Jotteq Inc., Nemera, Nipro Corporation, Ocular Therapeutix, Inc., Owen Mumford, Silgan Holdings Inc., Terumo Corporation, West Pharmaceuticals Services, Inc., Kedalion Therapeutics, Inc., Re-Vana Therapeutics, Inc., Biocorp, and Ocumedic, Inc.Who should buy this report?• Ophthalmic Drug Delivery Devices Manufacturers (emerging and established) • Technology/non-healthcare companies planning to enter the ophthalmic drug delivery devices market through a platform, mobile application, or smart deviceHow can market intelligence on ophthalmic drug delivery devices market add value to your business’s decision-making process?• Aid in product development• Aid in understanding the pricing scenario of the products• Aid in understanding the regulatory scenario of the market in different regions• Aid in understanding the patent trend of the market• Help in targeting a segment for launching a new product• Aid in understanding the market potential of different technologies• Aid in understanding the end user requirement• Support in analyzing the market opportunities• Insights on the key companies in the marketScope of the Global Ophthalmic Drug Delivery Devices Market Report:The scope of the global ophthalmic drug delivery devices market is as follows:• Devices: The report considers various devices used for ophthalmic drug delivery. These include pre-filled syringes, multidose eyedroppers, contact lenses, add-on devices, mist sprayers, squeeze dispensers, and other devices such as ocular inserts and tubes, etc.• Moreover, vision correctness devices (contact lenses and spectacles, etc.), packaging material (vials and cartridges, etc.), syringe accessories and safety devices (seals and needles, etc.), eye masks, injector systems, custom-made ophthalmic drug delivery devices, drug delivery wearables (patches, etc.), drug delivery training solutions, and surgical equipment have not been considered in the scope of the report.Key Questions Answered:• What has been the impact of COVID-19 on the global ophthalmic drug delivery devices market?• What are the key technological trends influencing the global ophthalmic drug delivery devices market, and what is their potential in short-, mid-, and long-term duration?• What are the key regulations impacting the global ophthalmic drug delivery devices market?• Who are the key players in the global ophthalmic drug delivery devices market? • Which key strategy was most extensively used in the global ophthalmic drug delivery devices market?• What are the key factors influencing the growth of the global ophthalmic drug delivery devices market? What are the major opportunity areas for the companies operating in the market?• Which product sub-category is projected to witness accelerated growth in the global ophthalmic drug delivery devices market during the forecast period 2021-2030?• Which formulation type is projected to hold the largest share in the global ophthalmic drug delivery devices market during the forecast period 2021-2030?• What are the major sales channels in the global ophthalmic drug delivery devices market, and what is their growth potential during the forecast period 2021-2030?• Who are the key end users, and what is their respective share in the global ophthalmic drug delivery devices market?• What are the major key findings for the global ophthalmic drug delivery devices market across various regions?
Companies Mentioned :
Aero Pump GmbHAptarGroup, Inc.Bausch Health Companies Inc.Becton, Dickinson and CompanyEyePoint Pharmaceuticals, Inc.Gaplast GmbHGerresheimer AGJotteq Inc.NemeraNipro CorporationOcular Therapeutix, Inc.Owen MumfordSilgan Holdings Inc.Terumo CorporationWest Pharmaceutical Services, Inc.Kedalion Therapeutics, Inc.Re-Vana TherapeuticsMati Therapeutics, Inc.BiocorpOcumedic, Inc.
Press Release :
The global ophthalmic drug delivery devices market is projected to reach $537.8 million by 2030, reveals the premium market intelligence study by BIS Research. The study also highlights that the market is set to witness a CAGR of 6.17% during the period 2021-2030.The comprehensive study of the global ophthalmic drug delivery devices market by BIS Research extensively covers the following:• Market numbers on various ophthalmic drug delivery devices, formulations, sales channels, and end users• More than 100 products present in the market• Market share analysis for ophthalmic drug delivery devices• Detailed global and regional market share analysis, including the scrutiny of 21 countries • Study of data of more than 30 companiesOcular or ophthalmic conditions have become one of the primary concerns in the global healthcare ecosystem. For instance, according to the World Health Organization (WHO)’s World Report on Vision report, published in October 2019, approximately 2.2 billion people suffer from some form of vision condition around the world. Furthermore, out of the 2.2 billion people impacted, 1 billion people suffer from a preventable or undiagnosed form of impairment. Moreover, the prevalence of ocular disorders is rising unequally, with low- and mid-income countries being adversely impacted. The integration of technology in ophthalmic drug delivery is projected to increase medication adherence and ensure sustained drug delivery. Furthermore, key players in the market comprise key medical device companies and emerging players. The emerging players are focusing on the development of advanced ophthalmic drug delivery devices.However, owing to the COVID-19 pandemic, the market’s growth declined in 2020. The shutdown of elective procedures and disruption in supply chains were the major factors for the market decline. However, the market is expected to normalize from 2021 as the surgeries resume.Also, the global ophthalmic drug delivery devices market is expected to be influenced by various trends such as sustained drug delivery, connected devices for medication adherence, small molecules for drug delivery, and liquid sprays.Key Companies Operating in the MarketLeading companies, market participants, and vendors operating in the market include Aero Pump GmbH, AptarGroup, Inc., Bausch Health Companies Inc., Becton, Dickinson and Company, EyePoint Pharmaceuticals, Inc., Gaplast GmbH, Gerresheimer AG, Jotteq Inc., Nemera, Nipro Corporation, Ocular Therapeutix, Inc., Owen Mumford, Silgan Holdings Inc., Terumo Corporation, West Pharmaceuticals Services, Inc., Kedalion Therapeutics, Inc., Re-Vana Therapeutics, Inc., Biocorp, and Ocumedic, Inc.Who should buy this report?• Ophthalmic Drug Delivery Devices Manufacturers (emerging and established) • Technology/non-healthcare companies planning to enter the ophthalmic drug delivery devices market through a platform, mobile application, or smart deviceHow can market intelligence on ophthalmic drug delivery devices market add value to your business’s decision-making process?• Aid in product development• Aid in understanding the pricing scenario of the products• Aid in understanding the regulatory scenario of the market in different regions• Aid in understanding the patent trend of the market• Help in targeting a segment for launching a new product• Aid in understanding the market potential of different technologies• Aid in understanding the end user requirement• Support in analyzing the market opportunities• Insights on the key companies in the marketScope of the Global Ophthalmic Drug Delivery Devices Market Report:The scope of the global ophthalmic drug delivery devices market is as follows:• Devices: The report considers various devices used for ophthalmic drug delivery. These include pre-filled syringes, multidose eyedroppers, contact lenses, add-on devices, mist sprayers, squeeze dispensers, and other devices such as ocular inserts and tubes, etc.• Moreover, vision correctness devices (contact lenses and spectacles, etc.), packaging material (vials and cartridges, etc.), syringe accessories and safety devices (seals and needles, etc.), eye masks, injector systems, custom-made ophthalmic drug delivery devices, drug delivery wearables (patches, etc.), drug delivery training solutions, and surgical equipment have not been considered in the scope of the report.Key Questions Answered:• What has been the impact of COVID-19 on the global ophthalmic drug delivery devices market?• What are the key technological trends influencing the global ophthalmic drug delivery devices market, and what is their potential in short-, mid-, and long-term duration?• What are the key regulations impacting the global ophthalmic drug delivery devices market?• Who are the key players in the global ophthalmic drug delivery devices market? • Which key strategy was most extensively used in the global ophthalmic drug delivery devices market?• What are the key factors influencing the growth of the global ophthalmic drug delivery devices market? What are the major opportunity areas for the companies operating in the market?• Which product sub-category is projected to witness accelerated growth in the global ophthalmic drug delivery devices market during the forecast period 2021-2030?• Which formulation type is projected to hold the largest share in the global ophthalmic drug delivery devices market during the forecast period 2021-2030?• What are the major sales channels in the global ophthalmic drug delivery devices market, and what is their growth potential during the forecast period 2021-2030?• Who are the key end users, and what is their respective share in the global ophthalmic drug delivery devices market?• What are the major key findings for the global ophthalmic drug delivery devices market across various regions?
Headline :
Global Ophthalmic Drug Delivery Devices Market to Reach $537.8 Million by 2030
Table of Contents :
1 Product Definition2 Scope of Research2.1 Scope of Study2.2 Inclusion and Exclusion Criteria2.2.1 Inclusion Criteria2.2.2 Exclusion Criteria2.3 Key Questions Answered in the Report3 Research Methodology3.1 Data Collection and Analysis3.2 Data Sources3.2.1 Primary Data Sources3.2.2 Secondary Data Sources3.3 Data Triangulation3.4 Market Estimation3.5 Forecast Period Selection Criteria3.6 Assumptions and Limitations4 Impact of COVID-19 on Ophthalmic Drug Delivery Devices4.1 Impact on Treatment Facilities4.2 Impact on Market Size4.2.1 Scenario Comparative Analysis (Pre-COVID-19, During COVID-19, Post-COVID-19)4.3 Future Outlook and Recommendations5 Industry Analysis5.1 Technology and Innovation Landscape5.1.1 Key Trends5.1.1.1 Short-Term Impact5.1.1.2 Mid-Term Impact5.1.1.3 Long-Term Impact5.1.1.4 Future Outlook5.2 Epidemiological Landscape5.2.1 Glaucoma5.2.2 Age-Related Macular Degeneration5.2.3 Cataract5.3 Value Chain Analysis5.4 End User Perceptions5.5 Regulatory Framework5.5.1 Regulatory Framework in North America5.5.1.1 Key Takeaways5.5.2 Regulatory Framework in Europe5.5.2.1 Key Takeaways5.5.3 Regulatory Framework in Asia-Pacific5.5.3.1 Key Takeaways5.6 Patent Analysis5.6.1 Patent Filed, by Year5.6.2 Patent Filed, by Country/Cluster5.7 Product Benchmarking6 Competitive Landscape6.1 Market Share Analysis6.2 Key Strategies and Developments6.2.1 Regulatory and Legal Activities6.2.2 Partnerships, Alliances, and Business Expansions6.2.3 New Offerings6.2.4 Funding Activities6.2.5 Mergers and Acquisitions6.3 Business Model Analysis6.4 Key Players-Competitive Benchmarking7 Global Ophthalmic Drug Delivery Devices Market Scenario7.1 Assumptions and Limitations7.2 Key Findings and Opportunity Assessment7.2.1 Key Findings7.2.2 Opportunity Assessment7.3 Global Ophthalmic Drug Delivery Devices Market Size and Forecast7.3.1 Realistic Growth Scenario7.3.2 Pessimistic/Conservative Growth Scenario7.3.3 Optimistic Scenario7.4 Market Dynamics7.4.1 Impact Analysis7.4.2 Market Growth Promoting Factors7.4.2.1 Increasing Prevalence of Ocular Disorders7.4.2.2 Development of Novel Drug Dispensers7.4.2.3 Integration of Digital Solutions in Ophthalmic Drug Delivery Devices7.4.2.4 Regular Funding Cycles for Emerging Companies7.4.3 Market Growth Restraining Factors7.4.3.1 High Upfront Cost of Advanced Ophthalmic Drug Delivery Devices7.4.3.2 Prolonged Regulatory Approval Process7.4.4 Market Opportunities7.4.4.1 Entry of Regional Companies in Global Ophthalmic Drug Delivery Devices Market7.4.4.2 Partnerships between Companies and Ophthalmic Clinics7.4.4.3 Inclusion of Nanotechnology in Ophthalmic Drugs Formulation7.4.4.4 Opportunities Potential7.4.4.4.1 Short-Term7.4.4.4.2 Mid-Term7.4.4.4.3 Long-Term8 Global Ophthalmic Drug Delivery Devices Market (by Product), 2018-20308.1 Growth Share Matrix8.2 Pre-Filled Syringes8.3 Multidose Eyedroppers8.4 Squeeze Dispenser8.5 Mist Sprayers8.6 Add-On Devices8.7 Contact Lenses8.8 Others (Tubes, Ocular Inserts)9 Global Ophthalmic Drug Delivery Devices Market (by Formulation), 2018-20309.1 Growth Share Matrix9.2 Eye Drops9.3 Liquid Sprays9.4 Ointments9.5 Gels9.6 Others (Emulsions, Suspensions, Etc.)10 Global Ophthalmic Drug Delivery Devices Market (by Sales Channel), 2018-203010.1 Opportunity Assessment10.2 Growth Share Matrix10.3 Direct Sales10.4 Indirect Sales11 Global Ophthalmic Drug Delivery Devices Market (by End User), 2018-203011.1 Opportunity Assessment11.2 Hospitals11.3 Clinics11.4 Homecare Settings11.5 Others (Standalone, Specialty Centers)12 Global Ophthalmic Drug Delivery Devices Market (by Region), 2018-203012.1 Overview12.2 North America Ophthalmic Drug Delivery Devices Market12.2.1 Key Findings and Opportunity Assessment12.2.2 Market Dynamics: Impact Analysis12.2.3 Market Size and Forecast12.2.3.1 by Sales Channel12.2.3.2 by End User12.2.3.3 by Country12.2.3.3.1 U.S.12.2.3.3.2 Canada12.3 Europe Ophthalmic Drug Delivery Devices Market12.3.1 Key Findings and Opportunity Assessment12.3.2 Market Dynamics: Impact Analysis12.3.3 Market Size and Forecast12.3.3.1 by Sales Channel12.3.3.2 by End User12.3.3.3 by Country12.3.3.3.1 Germany12.3.3.3.2 U.K.12.3.3.3.3 France12.3.3.3.4 Italy12.3.3.3.5 Spain12.3.3.3.6 Nordic Countries12.3.3.3.7 Rest-of-Europe12.4 Asia-Pacific Ophthalmic Drug Delivery Devices Market12.4.1 Key Findings and Opportunity Assessment12.4.2 Market Dynamics: Impact Analysis12.4.3 Market Size and Forecast12.4.3.1 by Sales Channel12.4.3.2 by End User12.4.3.3 by Country12.4.3.3.1 Japan12.4.3.3.2 China12.4.3.3.3 India12.4.3.3.4 South Korea12.4.3.3.5 Australia and New Zealand12.4.3.3.6 Singapore12.4.3.3.7 Rest-of-Asia-Pacific12.5 Latin America Ophthalmic Drug Delivery Devices Market12.5.1 Key Findings and Opportunity Assessment12.5.2 Market Dynamics: Impact Analysis12.5.3 Market Size and Forecast12.5.3.1 by Sales Channel12.5.3.2 by End User12.5.3.3 by Country12.5.3.3.1 Brazil12.5.3.3.2 Mexico12.5.3.3.3 Argentina12.5.3.3.4 Colombia12.5.3.3.5 Rest-of-Latin America12.6 Middle East and Africa Ophthalmic Drug Delivery Devices Market12.6.1 Key Findings and Opportunity Assessment12.6.2 Market Dynamics: Impact Analysis12.6.3 Market Size and Forecast12.6.3.1 by Sales Channel12.6.3.2 by End User12.6.3.3 by Country12.6.3.3.1 K.S.A.12.6.3.3.2 Israel12.6.3.3.3 South Africa12.6.3.3.4 Rest-of-Middle East and Africa13 Company Profiles13.1 Overview13.2 Established Companies13.2.1 Aero Pump GmbH13.2.1.1 Company Overview13.2.1.2 Role of Aero Pump GmbH in Global Ophthalmic Drug Delivery Devices Market13.2.1.3 SWOT Analysis13.2.2 AptarGroup, Inc.13.2.2.1 Company Overview13.2.2.2 Role of AptarGroup, Inc. in Global Ophthalmic Drug Delivery Devices Market13.2.2.3 Financials13.2.2.4 R&D Insights13.2.2.5 Recent Developments13.2.2.6 SWOT Analysis13.2.3 Bausch Health Companies Inc.13.2.3.1 Company Overview13.2.3.2 Role of Bausch Health Companies Inc. in Global Ophthalmic Drug Delivery Devices Market13.2.3.3 Financials13.2.3.4 R&D Insights13.2.3.5 Recent Developments13.2.3.6 SWOT Analysis13.2.4 Becton, Dickinson and Company13.2.4.1 Company Overview13.2.4.2 Role of Becton, Dickinson and Company in the Global Ophthalmic Drug Delivery Devices Market13.2.4.3 Financials13.2.4.4 R&D Insights13.2.4.5 Recent Developments13.2.4.6 SWOT Analysis13.2.5 EyePoint Pharmaceuticals, Inc.13.2.5.1 Company Overview13.2.5.2 Role of EyePoint Pharmaceuticals, Inc. in Global Ophthalmic Drug Delivery Devices Market13.2.5.3 Financials13.2.5.4 R&D Insights13.2.5.5 Recent Developments13.2.5.6 SWOT Analysis13.2.6 Gaplast GmbH13.2.6.1 Company Overview13.2.6.2 Role of Gaplast GmbH in Global Ophthalmic Drug Delivery Devices Market13.2.6.3 Recent Developments13.2.6.4 SWOT Analysis13.2.7 Gerresheimer AG13.2.7.1 Company Overview13.2.7.2 Role of Gerresheimer AG in Global Ophthalmic Drug Delivery Devices Market13.2.7.3 Financials13.2.7.4 R&D Insights13.2.7.5 Recent Developments13.2.7.6 SWOT Analysis13.2.8 Jotteq Inc.13.2.8.1 Company Overview13.2.8.2 Role of Jotteq Inc. in Global Ophthalmic Drug Delivery Devices Market13.2.8.3 SWOT Analysis13.2.9 Nemera13.2.9.1 Company Overview13.2.9.2 Role of Nemera in Global Ophthalmic Drug Delivery Devices Market13.2.9.3 Recent Developments13.2.9.4 SWOT Analysis13.2.10 Nipro Corporation13.2.10.1 Company Overview13.2.10.2 Role of Nipro Corporation in Global Ophthalmic Drug Delivery Devices Market13.2.10.3 Financials13.2.10.4 R&D Insights13.2.10.5 Recent Developments13.2.10.6 SWOT Analysis13.2.11 Ocular Therapeutix, Inc.13.2.11.1 Company Overview13.2.11.2 Role of Ocular Therapeutix, Inc. in Global Ophthalmic Drug Delivery Devices Market13.2.11.3 Financials13.2.11.4 R&D Insights13.2.11.5 Recent Developments13.2.11.6 SWOT Analysis13.2.12 Owen Mumford13.2.12.1 Company Overview13.2.12.2 Role of Owen Mumford in the Global Ophthalmic Drug Delivery Devices Market13.2.12.3 SWOT Analysis13.2.13 Silgan Holdings Inc.13.2.13.1 Company Overview13.2.13.2 Role of Silgan Holdings Inc. in Global Ophthalmic Drug Delivery Devices Market13.2.13.3 Financials13.2.13.4 SWOT Analysis13.2.14 Terumo Corporation13.2.14.1 Company Overview13.2.14.2 Role of Terumo Corporation in Global Ophthalmic Drug Delivery Devices Market13.2.14.3 Financials13.2.14.4 R&D Insights13.2.14.5 Recent Developments13.2.14.6 SWOT Analysis13.2.15 West Pharmaceutical Services, Inc.13.2.15.1 Company Overview13.2.15.2 Role of West Pharmaceutical Services, Inc. in the Global Ophthalmic Drug Delivery Devices Market13.2.15.3 Financials13.2.15.4 R&D Insights13.2.15.5 SWOT Analysis13.3 Company Snapshots13.3.1 Kedalion Therapeutics, Inc.13.3.1.1 Company Overview13.3.1.2 Role of Kedalion Therapeutics, Inc. in Global Ophthalmic Drug Delivery Devices Market13.3.1.3 Recent Developments13.3.2 Re-Vana Therapeutics13.3.2.1 Company Overview13.3.2.2 Role of Re-Vana Therapeutics in Global Ophthalmic Drug Delivery Devices Market13.3.2.3 Recent Developments13.3.3 Mati Therapeutics, Inc.13.3.3.1 Company Overview13.3.3.2 Role of Mati Therapeutics, Inc. in Global Ophthalmic Drug Delivery Devices Market13.3.4 Biocorp13.3.4.1 Company Overview13.3.4.2 Role of Biocorp in Global Ophthalmic Drug Delivery Devices Market13.3.4.3 Recent Developments13.3.5 Ocumedic, Inc.13.3.5.1 Company Overview13.3.5.2 Role of Ocumedic, Inc. in Global Ophthalmic Drug Delivery Devices Market13.3.5.3 Recent DevelopmentsList of Tables Table 1: Global Estimates of Common Ocular ConditionsTable 2: Global Ophthalmic Drug Delivery Devices Market, Quarterly Regional Impact, 2020Table 2.1: Global Ophthalmic Drug Delivery Devices Market, Exclusion CriteriaTable 4.1: Pre-COVID-19 Patient Volume in Private Ophthalmology Practices, July 2020Table 5.1: Regulatory Framework in North AmericaTable 5.2: Regulatory Framework in EuropeTable 5.3: Regulatory Framework in Asia-PacificTable 5.4: Global Ophthalmic Drug Delivery Devices Market: Product BenchmarkingTable 6.1: Global Ophthalmic Drug Delivery Devices Market, Business Model AnalysisTable 7.1: Global Ophthalmic Drug Delivery Devices Market, Funding CyclesTable 12.1: Prevalence of Ocular Disorders in North America, 2016, 2019, and 2030Table 12.2: North America Ophthalmic Drug Delivery Devices Market, Impact AnalysisTable 12.3: Prevalence of Ocular Disorders in the U.S., 2000, 2010, and 2019Table 12.4: Prevalence of Ocular Disorders in Canada, 2000, 2010, and 2019Table 12.5: Prevalence of Ocular Disorders in Europe, 2016, 2019, and 2030Table 12.6: Europe Ophthalmic Drug Delivery Devices Market, Impact AnalysisTable 12.7: Prevalence of Ocular Disorders in Germany, 2000, 2010, and 2019Table 12.8: Prevalence of Ocular Disorders in the U.K., 2000, 2010, and 2019Table 12.9: Prevalence of Ocular Disorders in France, 2000, 2010, and 2019Table 12.10: Prevalence of Ocular Disorders in Italy, 2000, 2010, and 2019Table 12.11: Prevalence of Ocular Disorders in Spain, 2000, 2010, and 2019Table 12.12: Prevalence of Ocular Disorders in Nordic Countries, 2000, 2010, and 2019Table 12.13: Prevalence of Ocular Disorders in Asia-Pacific, 2016, 2019, and 2030Table 12.14: Asia-Pacific Ophthalmic Drug Delivery Devices Market, Impact AnalysisTable 12.15: Prevalence of Ocular Disorders in Japan, 2000, 2010, and 2019Table 12.16: Prevalence of Ocular Disorders in China, 2000, 2010, and 2019Table 12.17: Prevalence of Ocular Disorders in India, 2000, 2010, and 2019Table 12.18: Prevalence of Ocular Disorders in South Korea, 2000, 2010, and 2019Table 12.19: Prevalence of Ocular Disorders in Australia and New Zealand, 2000, 2010, and 2019Table 12.20: Prevalence of Ocular Disorders in Singapore, 2000, 2010, and 2019Table 12.21: Prevalence of Ocular Disorders in Latin America, 2016, 2019, and 2030Table 12.22: Latin America Ophthalmic Drug Delivery Devices Market, Impact AnalysisTable 12.23: Prevalence of Ocular Disorders in Brazil, 2000, 2010, and 2019Table 12.24: Prevalence of Ocular Disorders in Mexico, 2000, 2010, and 2019Table 12.25: Prevalence of Ocular Disorders in Argentina, 2000, 2010, and 2019Table12.26: Prevalence of Ocular Disorders in Colombia, 2000, 2010, and 2019Table 12.27: Prevalence of Ocular Disorders in Middle East and Africa, 2016, 2019, and 2030Table 12.28: Middle East and Africa Ophthalmic Drug Delivery Devices Market, Impact AnalysisTable 12.29: Prevalence of Ocular Disorders in the K.S.A., 2000, 2010, and 2019Table 12.30: Prevalence of Ocular Disorders in Israel, 2000, 2010, and 2019Table 12.31: Prevalence of Ocular Disorders in South Africa, 2000, 2010, and 2019List of Figures Figure 1: Global Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 2: Global Ophthalmic Drug Delivery Devices Market, Impact AnalysisFigure 3: Global Ophthalmic Drug Delivery Devices Market, Companies BenchmarkingFigure 4: Global Ophthalmic Drug Delivery Devices Market (by End User), 2018 and 2030Figure 5: Global Ophthalmic Drug Delivery Devices Market (by Region), 2018 and 2030Figure 2.1: Global Ophthalmic Drug Delivery Devices Market SegmentationFigure 3.1: Global Ophthalmic Drug Delivery Devices Market: Research MethodologyFigure 3.2: Primary ResearchFigure 3.3: Secondary ResearchFigure 3.4: Data TriangulationFigure 3.5: Assumptions and LimitationsFigure 4.1: Global Ophthalmic Drug Delivery Devices Market, Scenario Comparative AnalysisFigure 5.1: Global Ophthalmic Drug Delivery Devices Market: Key TrendsFigure 5.2: Global Ophthalmic Drug Delivery Devices Market, Short-Term Impact of Key TrendsFigure 5.3: Global Ophthalmic Drug Delivery Devices Market, Mid-Term Impact of Key TrendsFigure 5.4: Global Ophthalmic Drug Delivery Devices Market, Long-Term Impact of Key TrendsFigure 5.5: Global Prevalence, Glaucoma, 2016-2030Figure 5.6: Glaucoma Prevalence, by Region, 2016-2030Figure 5.7: Global Prevalence, Age-Related Macular Degeneration, 2016-2030Figure 5.8: Age-Related Macular Degeneration Prevalence, by Region, 2016-2030Figure 5.9: Global Prevalence, Cataract, 2016-2030Figure 5.10: Cataract Prevalence, by Region, 2016-2030Figure 5.11: Global Ophthalmic Drug Delivery Devices Market: Value Chain AnalysisFigure 5.12: Global Ophthalmic Drug Delivery Devices Market: End User PerceptionFigure 5.13: Global Ophthalmic Drug Delivery Devices Market, Patent Filing Trend, January 2016-July 2021Figure 5.14: Global Ophthalmic Drug Delivery Devices Market, Patent Filing Trend (by Country)Figure 6.1: Global Ophthalmic Drug Delivery Devices Market Share Analysis (by Company), 2020Figure 6.2: Share of Key Developments and Strategies in the Global Ophthalmic Drug Delivery Devices Market (by Category), January 2018-June 2021Figure 6.3: Regulatory and Legal Activities (by Company), January 2018-June 2021Figure 6.4: Partnerships, Alliances, and Business Expansions (by Company), January 2018-June 2021Figure 6.5: New Offerings (by Company), January 2018-June 2021Figure 6.6: Funding Activities (by Company), January 2018-June 2021Figure 6.7: Mergers and Acquisitions (by Company), January 2018-June 2021Figure 6.8: Global Ophthalmic Drug Delivery Devices Market, Growth Share Matrix (by Product), 2018-2030Figure 7.1: Global Ophthalmic Drug Delivery Devices Market, Realistic Growth Scenario, $Million, 2018-2030Figure 7.2: Global Ophthalmic Drug Delivery Devices Market, Pessimistic/Conservative Growth Scenario, $Million, 2018-2030Figure 7.3: Global Ophthalmic Drug Delivery Devices Market, Optimistic Growth Scenario, $Million, 2018-2030Figure 7.4: Global Ophthalmic Drug Delivery Devices Market, Impact AnalysisFigure 7.5: Increasing Prevalence of Ocular Disorders, 2016-2019Figure 8.1: Global Ophthalmic Drug Delivery Devices Market, Incremental Opportunity, (by Product), $Million, 2018 and 2030Figure 8.2: Global Ophthalmic Drug Delivery Devices Market (by Product), Growth Share MatrixFigure 8.3: Global Ophthalmic Drug Delivery Devices Market (Pre-Filled Syringes), $Million, 2018-2030Figure 8.4: Global Ophthalmic Drug Delivery Devices Market (Multidose Eyedroppers), $Million, 2018-2030Figure 8.5: Global Ophthalmic Drug Delivery Devices Market (Squeeze Dispenser), $Million, 2018-2030Figure 8.6: Global Ophthalmic Drug Delivery Devices Market (Mist Sprayers), $Million, 2018-2030Figure 8.7: Global Ophthalmic Drug Delivery Devices Market (Add-On Devices), $Million, 2018-2030Figure 8.8: Global Ophthalmic Drug Delivery Devices Market (Contact Lenses), $Million, 2018-2030Figure 8.9: Global Ophthalmic Drug Delivery Devices Market (Others), $Million, 2018-2030Figure 9.1: Global Ophthalmic Drug Delivery Devices Market, Incremental Opportunity, (by Formulation), $Million, 2018 and 2030Figure 9.2: Global Ophthalmic Drug Delivery Devices Market (by Formulation), Growth Share MatrixFigure 9.3: Global Ophthalmic Drug Delivery Devices Market (Eye Drops), $Million, 2018-2030Figure 9.4: Global Ophthalmic Drug Delivery Devices Market (Liquid Sprays), $Million, 2018-2030Figure 9.5: Global Ophthalmic Drug Delivery Devices Market (Ointments), $Million, 2018-2030Figure 9.6: Global Ophthalmic Drug Delivery Devices Market (Gels), $Million, 2018-2030Figure 9.7: Global Ophthalmic Drug Delivery Devices Market (Others), $Million, 2018-2030Figure 10.1: Global Ophthalmic Drug Delivery Devices Market, Incremental Opportunity, (by Sales Channel), $Million, 2018 and 2030Figure 10.2: Global Ophthalmic Drug Delivery Devices Market (by Sales Channel), Growth Share MatrixFigure 10.3: Global Ophthalmic Drug Delivery Devices Market (Direct Sales), $Million, 2018-2030Figure 10.4: Global Ophthalmic Drug Delivery Devices Market (Indirect Sales), $Million, 2018-2030Figure 11.1: Global Ophthalmic Drug Delivery Devices Market (by End User), Incremental Opportunity, (by End User), $Million, 2018 and 2030Figure 11.2: Global Ophthalmic Drug Delivery Devices Market (Hospitals), $Million, 2018-2030Figure 11.3: Global Ophthalmic Drug Delivery Devices Market (Clinics), $Million, 2018-2030Figure 11.4: Global Ophthalmic Drug Delivery Devices Market (Homecare Settings), $Million, 2018-2030Figure 11.5: Global Ophthalmic Drug Delivery Devices Market (Others), $Million, 2018-2030Figure 12.1: Global Ophthalmic Drug Delivery Devices Market, (by Region), 2018 and 2030Figure 12.2: North America Ophthalmic Drug Delivery Devices Market, Incremental Growth Opportunity, $Million, 2018 and 2030Figure 12.3: North America Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.4: North America Ophthalmic Drug Delivery Devices Market, (by Sales Channel), $Million, 2018-2030Figure 12.5: North America Ophthalmic Drug Delivery Devices Market, (by End User), $Million, 2018-2030Figure 12.6: North America Ophthalmic Drug Delivery Devices Market (by Country)Figure 12.7: U.S. Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.8: Canada Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.9: Europe Ophthalmic Drug Delivery Devices Market, Incremental Growth Opportunity, $Million, 2018 and 2030Figure 12.10: Europe Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.11: Europe Ophthalmic Drug Delivery Devices Market, (by Sales Channel), $Million, 2018-2030Figure 12.12: Europe Ophthalmic Drug Delivery Devices Market, (by End User), $Million, 2018-2030Figure 12.13: Europe Ophthalmic Drug Delivery Devices Market (by Country)Figure 12.14: Germany Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.15: U.K. Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.16: France Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.17: Italy Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.18: Spain Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.19: Nordic Countries Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.20: Rest-of-Europe Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.21: Asia-Pacific Ophthalmic Drug Delivery Devices Market, Incremental Growth Opportunity, $Million, 2018 and 2030Figure 12.22: Asia-Pacific Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.23: Asia-Pacific Ophthalmic Drug Delivery Devices Market, (by Sales Channel), $Million, 2018-2030Figure 12.24: Asia-Pacific Ophthalmic Drug Delivery Devices Market, (by End User), $Million, 2018-2030Figure 12.25: Asia-Pacific Ophthalmic Drug Delivery Devices Market (by Country)Figure 12.26: Japan Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.27: China Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.28: India Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.29: South Korea Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.30: Australia and New Zealand Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.31: Singapore Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.32: Rest-of-Asia-Pacific Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.33: Latin America Ophthalmic Drug Delivery Devices Market, Incremental Growth Opportunity, $Million, 2018 and 2030Figure 12.34: Latin America Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.35: Latin America Ophthalmic Drug Delivery Devices Market, (by Sales Channel), $Million, 2018-2030Figure 12.36: Latin America Ophthalmic Drug Delivery Devices Market, (by End User), $Million, 2018-2030Figure 12.37: Latin America Ophthalmic Drug Delivery Devices Market (by Country)Figure 12.38: Brazil Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.39: Mexico Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.40: Argentina Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.41: Colombia Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.42: Rest-of-Latin America Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.43: Middle East and Africa Ophthalmic Drug Delivery Devices Market, Incremental Growth Opportunity, $Million, 2018 and 2030Figure 12.44: Middle East and Africa Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.45: Middle East and Africa Ophthalmic Drug Delivery Devices Market, (by Sales Channel), $Million, 2018-2030Figure 12.46: Middle East and Africa Ophthalmic Drug Delivery Devices Market, (by End User), $Million, 2018-2030Figure 12.47: Middle East and Africa Ophthalmic Drug Delivery Devices Market (by Country)Figure 12.48: K.S.A. Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.49: Israel Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.50: South Africa Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 12.51: Rest-of-Middle East and Africa Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030Figure 13.1: Shares of Key Companies ProfiledFigure 13.2: Aero Pump GmbH: Overall Product PortfolioFigure 13.3: Aero Pump GmbH: SWOT AnalysisFigure 13.4: AptarGroup, Inc.: Overall Product PortfolioFigure 13.5: AptarGroup, Inc.: Overall Financials, 2018-2020Figure 13.6: AptarGroup, Inc.: Net Revenue (by Segment), $Million, 2018-2020Figure 13.7: AptarGroup, Inc.: Net Revenue (by Region), $Million, 2018-2020Figure 13.8: AptarGroup, Inc.: R&D Expenditure, 2018-2020Figure 13.9: AptarGroup, Inc: SWOT AnalysisFigure 13.10: Bausch Health Companies Inc.: Overall Product PortfolioFigure 13.11: Bausch Health Companies Inc.: Overall Financials, 2018-2020Figure 13.12: Bausch Health Companies Inc.: Revenue (by Segment), 2018-2020Figure 13.13: Bausch Health Companies Inc.: Revenue (by Region), 2018-2020Figure 13.14: Bausch Health Companies Inc.: R&D Expense, 2018-2020Figure 13.15: Bausch Health Companies Inc.: SWOT AnalysisFigure 13.16: Becton, Dickinson and Company: Overall Product PortfolioFigure 13.17: Becton, Dickinson and Company: Overall Financials, 2018-2020Figure 13.18: Becton, Dickinson and Company: Net Revenue (by Segment), $Million, 2018-2020Figure 13.19: Becton, Dickinson and Company: Net Revenue (by Region), $Million, 2018-2020Figure 13.20: Becton, Dickinson and Company: R&D Expenditure, 2018-2020Figure 13.21: Becton, Dickinson and Company: SWOT AnalysisFigure 13.22: EyePoint Pharmaceuticals, Inc.: Overall Product PortfolioFigure 13.23: EyePoint Pharmaceuticals, Inc.: Overall Financials, 2018-2020Figure 13.24: EyePoint Pharmaceuticals, Inc.: Revenue (by Region), 2018-2020Figure 13.25: EyePoint Pharmaceuticals, Inc.: R&D Expenditure, 2018-2020Figure 13.26: EyePoint Pharmaceuticals, Inc.: SWOT AnalysisFigure 13.27: Gaplast GmbH: Overall Product PortfolioFigure 13.28: Gaplast GmbH: SWOT AnalysisFigure 13.29: Gerresheimer AG: Overall Product PortfolioFigure 13.30: Gerresheimer AG: Overall Financials, 2018-2020Figure 13.31: Gerresheimer AG: Revenue (by Segment), 2018-2020Figure 13.32: Gerresheimer AG: Revenue (by Region), 2018-2020Figure 13.33: Gerresheimer AG: R&D Expense, 2018-2020Figure 13.34: Gerresheimer AG: SWOT AnalysisFigure 13.35: Jotteq Inc.: Overall Product PortfolioFigure 13.36: Jotteq Inc.: SWOT AnalysisFigure 13.37: Nemera: Overall Product PortfolioFigure 13.38: Nemera: SWOT AnalysisFigure 13.39: Nipro Corporation: Overall Product PortfolioFigure 13.40: Nipro Corporation: Overall Financials, 2018-2020Figure 13.41: Nipro Corporation: Revenue (by Segment), 2018-2020Figure 13.42: Nipro Corporation: Revenue (by Region), 2018-2020Figure 13.43: Nipro Corporation: R&D Expense, 2018-2020Figure 13.44: Nipro Corporation: SWOT AnalysisFigure 13.45: Ocular Therapeutix, Inc.: Overall Product PortfolioFigure 13.46: Ocular Therapeutix, Inc.: Overall Financials, 2018-2020Figure 13.47: Ocular Therapeutix, Inc.: R&D Expense, 2018-2020Figure 13.48: Ocular Therapeutix, Inc.: SWOT AnalysisFigure 13.49: Owen Mumford: Overall Product PortfolioFigure 13.50: Owen Mumford: SWOT AnalysisFigure 13.51: Silgan Holdings Inc.: Overall Product PortfolioFigure 13.52: Silgan Holdings Inc.: Overall Financials, 2018-2020Figure 13.53: Silgan Holdings Inc.: Revenue (by Segment), 2018-2020Figure 13.54: Silgan Holdings Inc.: Revenue (by Region), 2018-2020Figure 13.55: Silgan Holdings Inc.: SWOT AnalysisFigure 13.56: Terumo Corporation: Overall Product PortfolioFigure 13.57: Terumo Corporation: Overall Financials, 2018-2020Figure 13.58: Terumo Corporation: Revenue (by Segment), 2018-2020Figure 13.59: Terumo Corporation: Revenue (by Region), 2018-2020Figure 13.60: Terumo Corporation: R&D Expense, 2018-2020Figure 13.61: Terumo Corporation: SWOT AnalysisFigure 13.62: West Pharmaceutical Services, Inc.: Overall Product PortfolioFigure 13.63: West Pharmaceutical Services, Inc.: Overall Financials, 2018-2020Figure 13.64: West Pharmaceutical Services, Inc.: Net Revenue (by Segment), $Million, 2018-2020Figure 13.65: West Pharmaceutical Services, Inc.: Net Revenue (by Region), $Million, 2018-2020Figure 13.66: West Pharmaceutical Services, Inc.: R&D Expenditure, 2018-2020Figure 13.67: West Pharmaceutical Services, Inc.: SWOT Analysis